A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms ATTRACTION-05
- Sponsors Ono Pharmaceutical
- 04 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 Mar 2024.
- 06 Jun 2023 First confirmatory results of N+C as postoperative adjuvant treatment, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 09 Mar 2023 Planned End Date changed from 1 Mar 2023 to 1 Oct 2023.